Drug intelligence / Profile preview

Hydroxyaminovaline

Development stage: Unknown
Modality: Small Molecules

Overview

Hydroxyaminovaline is a chemical compound with the molecular formula C5H12N2O2. It is identified as a pharmaceutical in chemical databases. However, specific therapeutic indications, detailed mechanisms of action, and its development status as a drug are not readily available in public records. Its chemical structure suggests it functions as a small molecule.

Other names: (2R)-2-amino-N-hydroxy-3-methylbutanamiden-hydroxy-d-valinamide

Targets

MMP13 (Matrix metalloproteinase-13)MMP3 (Matrix metalloproteinase-3)

Beyond the preview

Go deeper on Hydroxyaminovaline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hydroxyaminovaline.

Explore the full profile